Wave Life Sciences Taps Sanofi Exec as Chief Business Officer to Drive Growth
Event summary
- Wave Life Sciences appointed Dr. Monika Vnuk as Chief Business Officer on September 22, 2026.
- Dr. Vnuk received a stock option to purchase 375,000 shares, vesting over four years with an exercise price of $4.25 per share.
- Vnuk previously led global business development at Sanofi and managed late-stage product financing at Blackstone Life Sciences.
- She negotiated the Pfizer-BioNTech COVID-19 vaccine partnership during her tenure at Pfizer.
The big picture
Wave Life Sciences is bolstering its executive team with a seasoned business development leader as it advances its RNA medicines platform. Dr. Vnuk's background in high-stakes partnerships and asset financing suggests a strategic focus on scaling Wave's pipeline and securing value-creating deals. The move comes as the biotech industry increasingly turns to RNA-based therapies, positioning Wave to compete in a rapidly evolving market.
What we're watching
- Pipeline Expansion
- How Dr. Vnuk's experience will accelerate Wave's RNA medicines pipeline, particularly in obesity, liver disease, and rare disorders.
- Strategic Partnerships
- Whether Vnuk can replicate her success in negotiating high-value partnerships, such as the Pfizer-BioNTech deal, for Wave.
- Financial Performance
- The pace at which Wave can translate its differentiated RNA platform into revenue-generating transactions under Vnuk's leadership.
Related topics
